Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$16.43
-0.08 (-0.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $138.7M · quality 66.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.7B
P/E
136.9x
↑EV/EBITDA
47.6x
↑ROE
3.2%
↑Gross Margin
70.0%
↑Debt/Equity
0.52
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.3%
FCF CAGR
-7.2%
FCF margin
8.1%
FCF / Net income
3.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.70B · net income $46.3M · FCF $138.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.70B | $1.70B | $2.14B | $1.63B | $1.20B |
| Net Income | $46.3M | $46.3M | $274.0M | $292.7M | $201.3M |
| EBITDA | $152.9M | $152.9M | $415.4M | $375.1M | $244.0M |
| EPS | 0.11 | 0.11 | 0.67 | 0.71 | 0.49 |
| Gross Margin | 70.0% | 70.0% | 69.7% | 73.3% | 71.7% |
| Operating Margin | 11.7% | 11.7% | 16.2% | 17.3% | 18.6% |
| Net Margin | 2.7% | 2.7% | 12.8% | 17.9% | 16.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.52 | 0.52 | 0.40 | 0.38 | 0.17 |
| Current Ratio | 1.57 | 1.57 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $138.7M | $138.7M | $61.9M | $168.0M | $173.4M |
| Returns | |||||
| ROE | 3.2% | 3.2% | 17.9% | 19.9% | 16.2% |
| Valuation | |||||
| P/E | 136.92 | 136.92 | 18.67 | 27.15 | 31.29 |
| EV/EBITDA | 47.60 | 47.60 | 12.64 | 21.15 | 24.31 |
| P/B | 4.78 | 4.78 | 3.35 | 5.41 | 5.08 |
| Growth & Yield | |||||
| Revenue Growth | -20.6% | -20.6% | 31.2% | 36.1% | — |
| EPS Growth | -83.6% | -83.6% | -5.6% | 44.9% | — |
| Dividend Yield | 2.1% | 2.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
136.7%
EPS terminal req.
$1.46
Spread vs growth
-220.2%
5Y implied EPS CAGR
74.2%
EPS terminal req.
$1.76
Spread vs growth
-157.8%
10Y implied EPS CAGR
38.4%
EPS terminal req.
$2.84
Spread vs growth
-122.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+37.1%
Start / end P/E
18.2x → 149.4x
EPS bridge
0.67 → 0.11
Residual
-603.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.